期刊文献+

Waldenstrom巨球蛋白血症15例临床分析 被引量:3

Clinical analysis of 15 patients with Waldenstrom macroglobulinemia
原文传递
导出
摘要 目的探讨Waldenstrom巨球蛋白血症(WM)的临床特点,提高对这种疾病的认识及诊治水平。方法对本院1995年11月至2007年10月确诊为WM的15例患者进行回顾性分析。结果患者的中位发病年龄68.5(60~79)岁,男/女=2.75/1。患者的主要表现为乏力、消瘦、脾大、淋巴结肿大。15例患者分别接受烷化剂、核苷类似物、沙立度胺、硼替佐米等治疗。15例患者的随访时间为4个月~10年,中位随访时间82个月。结论WM多发于老年人,男性多见,临床表现多样,化疗是主要的治疗手段,但不能治愈,新药硼替佐米,沙立度胺有望提高WM的疗效。 Objective To explore the clinical characteristics of Waldenstrom macroglobulinemia (WM) and enhance the level of diagnosis and treatment. Method The data of 15 patients with WM in our hospital from November 1995 to October 2007 were retrospectively analyzed. Results The median age was 68. 5 ( 60-79 ) years, male/female = 2. 75/1. Main clinical manifestations were fatigue, loss of weight, splenomegaly and lymphadenopathy. All the patients accepted the treatment of alkylating agents, purine nueleoside analogs, bortezomib or thalidomide respectively. The follow-up period for the patients was 4 months to 10 years and the median follow-up time was 82 months. Conclusion WM may often be seen in old male patients with varied clinical manifestations. The primary treatment is chemotherapy, but the disease is incurable. Bortezomib and thalidomide may improve the therapeutic effect.
出处 《中华内科杂志》 CAS CSCD 北大核心 2009年第3期193-195,共3页 Chinese Journal of Internal Medicine
关键词 WALDENSTROM巨球蛋白血症 免疫球蛋白M 药物疗法 Waldenstrom maeroglobulinemia Immunoglobulin M Drug therapy
  • 引文网络
  • 相关文献

参考文献9

  • 1Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenstrom's macroglobulinemia. Hematology Am Soc Hematol Educ Program, 2004 : 257-282.
  • 2Dimopoulos MA, Alexanian R. Waldenstrom's macroglobulinemia. Blood, 1994, 83:1452-1459.
  • 3Moore DF Jr, Moulopoulos LA, Dimopoulos MA. Waldenstrom maeroglobulinemia presenting as a renal or perirenal mass: clinical and radiographic features. Leuk Lymphoma, 1995,17:331-334.
  • 4Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenstrom macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood, 2000, 96:852-858.
  • 5Chang H, Qi X, Xu W, et al. Analysis of 6q deletion in Waldenstrom macroglobulinemia. Eur J Haematol, 2007, 79:244-247.
  • 6Petrucci MT, Avvisati G, Tribalto M, et al. Waldenstrom's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients. J Intern Meal,1989, 226:443-447.
  • 7Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarbine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial ( Southwest Oncology Group S9003 ). Blood ,2001, 98:41-48.
  • 8Coleman M, Leonard J, Lyons L, et al. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol, 2003, 30 : 270- 274.
  • 9Treon SP, Hunter ZR, Matous J. Muhicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia. results of WMCTG Trial 03-248. Clin Cancer Res,2007,13:3320- 3325.

同被引文献13

  • 1Schuster SR,Rajkumar SV,Dispenzieri A,et al.IgM multiple myeloma:disease definition,prognosis,and differentiation from Waldenstrom's macroglobulinemia[J].Am J Hematol,2010,85:853-855.
  • 2Owen RG,Feyler S,O'Connor SJ,et al.Defining IgM multiple myeloma[J].Am J Hematol,2011,86:717.
  • 3Tembhare PR,Yuan CM,Venzon D,et al.Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases[J].Leuk Res,2014,38:371-376.
  • 4Feyler S,O'Connor SJ,Rawstron AC,et al.IgM myeloma:a rare entity characterized by a CD20-CD56-CD117-immunophenotype and the t(11 ; 14)[J].Br J Haematol,2008,140:547-551.
  • 5King RL,Howard MT,Hodnefield JM,et al.IgM multiple myeloma:pathologic evaluation of a rare entity[J].Am J Clin Pathol,2013,140:519-524.
  • 6Avet-Loiseau H,Garand R,Lodé L,et al.Translocation t(11; 14) (q13 ; q32) is the hallmark of IgM,IgE,and nonsecretory multiple myeloma variants[J].Blood,2003,101:1570-1571.
  • 7Ackroyd S,O'Connor SJ,Rawstron AC,et al.IgM myeloma with 4 ; 14) (p16 ; q32)[J].Cancer Genet Cytogenet,2005,162:183-184.
  • 8Owen RG,O'Connor SJ,Bond LR,et al.Translocation t(14; 16) in IgM multiple myeloma[J].Br J Haematol,2011,155:402-403.
  • 9Treon SP,Xu L,Yang G,et al.MYD88 L265P somatic mutation in Waldenstr(o)m's macroglobulinemia[J].N Engl J Med,2012,367:826-833.
  • 10Oka S,Yokote T,Akioka T,et ai.Successful treatment of multi agent chemotherapy with rituximab for IgM plasma cell leukemia[J].LeukRes,2006,30:1581-1583.

引证文献3

二级引证文献12

;
使用帮助 返回顶部